Loading
A phase 3 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy is a phase 3 interventional study registered as NCT04853342 by Allist Pharmaceuticals, Inc., with 318 participants planned, started 2021-06-07 and due to reach its primary completion in 2026-12. Interventions recorded: Drug: Furmonertinib 80 mg and Furmonertinib 80 mg placebo.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Furmonertinib, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.